TB vaccines: current status and future perspectives

Aagaard, Claus; Dietrich, Jes; Doherty, Mark; Andersen, Peter

doi:10.1038/icb.2009.14

Cited by 75 publications

(62 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both involving recombinant BCG, subunit vaccine and live attenuated Mycobacterium tuberculosis (Mtb) strains are currently under investigation. 2 Comparative genomics of the Mtb complex revealed that the attenuation of BCG is related to the loss of the protein secretion system ESX-1 due to deletion of the region of difference 1 (RD1) locus. 3 This segment is localized close to the origin of replication in all fully virulent members of the complex and harbors genes esxA (Rv3875), coding for the 6-kDa early secreted antigenic target (ESAT-6), and esxB (Rv3874), encoding the 10-kDa culture filtrate protein (CFP-10).…”

Section: Mtb and Bcg Have Different Impacts On The Autophagic Processmentioning

confidence: 99%

ESX-1 dependent impairment of autophagic flux byMycobacterium tuberculosisin human dendritic cells

et al. 2012

View full text Add to dashboard Cite

Section: Mtb and Bcg Have Different Impacts On The Autophagic Processmentioning

confidence: 99%

ESX-1 dependent impairment of autophagic flux byMycobacterium tuberculosisin human dendritic cells

et al. 2012

View full text Add to dashboard Cite

“…Available TB treatment involves daily administration of four oral antibiotics for a period of six months or more [7]. Due to the high percentage of side effects (like ototoxicity and nephrotoxicity) and the extended duration of treatment results in low patient adherence [8]. History of tubercular chemotherapy started with discovery of streptomycin in 1944 [9].…”

Section: Introductionmentioning

confidence: 99%

Present status of nanoparticle research for treatment of Tuberculosis

2011

View full text Add to dashboard Cite

-Nanotechnology has offered enormous improvement in field of therapeutics by means of designing of drug delivery systems and opened the possibility of controlling infections at the molecular level. Nanocarriers can cross biological barriers and are able to target cellular reservoirs of Mycobacterium tuberculosis (M. tuberculosis). Nanoparticle-based systems have significant potential for treatment and prevention of tuberculosis (TB). A variety of nanocarriers have been widely evaluated as potential drug delivery systems for various administration routes. Targeting the drugs to certain physiological sites such as the lymph nodes has emerged as a promising strategy in treating TB with improved drug bioavailability and reduction of the dosing frequency. Nanotechnology based rational targeting may improve therapeutic success by limiting adverse drug effects and requiring less frequent administration regimes, ultimately resulting in more patients compliance and thus attain higher adherence levels. The development of nanoparticle based aerosol vaccine is undergoing which could serve as new platform for immunization. Present article compiles the general physiological aspects of the infection along with new research uptades on nanocarriers used in prevention of tuberculosis. _______________________________________________________________________________________

show abstract

“…Vaccine candidates currently in clinical trials include improved recombinant BCG vaccines, virus-based recombinant vaccines, and subunit vaccines comprised of dominant secreted antigens (1,32). Secreted proteins, regularly described as culture filtrate proteins (CFP), are the main targets of the T-cell response in mice, both at the height of infection and in a state of memory immunity, as well as in humans with active TB (1,4,5,7,23). Immunization with these antigens in the presence of different adjuvants provided protection in mice challenged with M. tuberculosis, and protection was mediated by gamma interferon (IFN-␥)-producing CD4 ϩ cells (29,38).…”

mentioning

confidence: 99%